Thimerosal Characterization In Children Should Be Research Focus - Zoon
Executive Summary
Characterization of thimerosal's effects in vaccinated children should constitute a significant portion of immediate research, balanced with research into new types of vaccine preservatives, FDA Center for Biologics Evaluation & Research Director Kathyrn Zoon, PhD, said at the National Vaccine Advisory Committee-sponsored workshop on thimerosal in vaccines Aug. 12.
You may also be interested in...
Vaccine Thimerosal Reduction Plans To Be Discussed At Public Meeting
Concrete plans and a realistic timeframe for vaccine manufacturers to eliminate or reduce thimerosal from their products will be discussed at a public workshop between manufacturers, Public Health Service agencies and the American Academy of Pediatrics.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials